Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Antares files NDA for Anturol gel in overactive bladder

Dec. 30, 2010

TRPV4 antagonists hold promise for the treatment of bladder dysfunction

Dec. 24, 2010

Recordati and Nymox sign licensing agreement for NX-1207 in BPH

Dec. 20, 2010

Merck & Co. divulges novel beta3-adrenoceptor agonists

Dec. 13, 2010

Long-term phase III study confirms efficacy of avanafil for erectile dysfunction

Dec. 7, 2010

Ikaria begins pivotal phase III Lucassin trial in hepatorenal syndrome type 1

Dec. 1, 2010

Atrasentan reduces albuminuria in patients with diabetes-associated nephropathy

Dec. 1, 2010

Keryx's short-term phase III trial of Zerenex meets primary endpoints

Nov. 30, 2010

Fresolimumab improves symptoms of primary focal segmental glomerulosclerosis in phase I trial

Nov. 30, 2010

PA-21 is safe and reduces hyperphosphatemia in subjects with CKD on hemodialysis

Nov. 26, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026